News | Mammography | October 22, 2020

Mammography Screening Also Saves Older Lives

Mammography, which is an X-ray picture of the breast, is efficient also for women over the age of 70.

Getty Images

October 22, 2020 — Mammography, which is an X-ray picture of the breast, is efficient also for women over the age of 70. For women invited to regular mammography screening over the age of 70, the reduction in mortality rate was significant. This according to a vast new study from Sweden.

"The results confirm that the Swedish assessment of setting the upper age limit for mammography screening to 74 was justified," said Håkan Jonsson, docent at the Department of Epidemiology and Global Health at Umeå University.

This new Swedish study builds upon 20 years of follow ups and over 2,000 breast cancer deaths. It turned out that the breast cancer mortality rate was 20 per cent lower for women invited to partake in mammography between the ages of 70 and 74 compared to those who were only invited up until the age of 69. For those who actually took part in screening, the mortality rate reduction was a full 27 per cent.

Mammography screening was introduced in the late 1980s after positive results from a number of randomised controlled trials of which several were conducted in Sweden. However, there have previously been uncertainties regarding what age groups should be included. As a result, countries have made different assessments and the recommendations have varied.

Currently, most countries offer screening for women up until the age of 69, but some countries - Sweden included - have chosen to set the upper age limit to 74. In Sweden, the screening programmes are decentralised which has meant that the upper age limit of 74 has been introduced at different points in the various parts of the country. This not least as the early recommendations from the Swedish National Board of Health and Welfare allowed regional exceptions of an upper age limit of 69.

In the current study, the breast cancer mortality rate in women in the areas of Sweden that used an upper age limit of 74 were compared to those regions that used an age limit of 69 between the years 1986 and 2012. The Cancer Register was used to identify women diagnosed with breast cancer aged 70-74 and the National Cause of Death Register was used to gain data on cause of death for those who died from breast cancer aged 70-89. Cause of death may be difficult to decide - particularly for older women. Consequently, the excess mortality in breast cancer cases was measured in conjunction with the underlying cause of death.

"Given that we live longer and remain active in old age, it is also valuable to screen for cancer in order to start treatment in time," says Håkan Jonsson.

Most randomised controlled trials were conducted about 40 years ago. Only one of those trials included women aged 70 to 74. Nevertheless, this group was too small to provide any clear evidence. Observational studies are rare in this age group as few countries have invited these women to screening. This also means that the evidence of the importance of mammography in women aged 70 to 74 has been scarce until now.

For more information: www.umu.se/en

 

Breast Imaging Videos:

VIDEO: Explaining Dense Breasts

VIDEO: The Impact of COVID-19 on Breast Imaging

 

Related Breast MRI Content:

Abbreviated MRI Outperforms 3-D Mammograms at Finding Cancer in Dense Breasts

VIDEO: Explaining Dense Breasts — Interview with Christiane Kuhl, M.D.

VIDEO: Use of Breast MRI Improved Cancer Detection in Dense Breasts in Dutch Study — Interview with Gillian Newstead, M.D.

Technologies to Watch in Breast Imaging

Screening MRI Detects BI-RADS 3 Breast Cancer in High-risk Patients

Rapid Breast MRI Screening Improves Cancer Detection in Dense Breasts

Breast MRI in Cancer Diagnosis

Related Content

A comparison of standard mammography imaging (left) in a woman with dense breasts and a breast MRI imaging study (right) showing a clearly defined cancer and is extremely hard to detect on the mammograms.

A comparison of standard mammography imaging (left) in a woman with dense breasts and a breast MRI imaging study (right) showing a clearly defined cancer and is extremely hard to detect on the mammograms. Images from Christiane Kuhl, M.D.

Feature | MRI Breast | March 04, 2021 | By Dave Fornell, Editor
Dense breast tissue can hide cancers i
Researchers said women who skip even one scheduled mammography screening before a breast cancer diagnosis face a significantly higher risk of dying from the cancer.

Getty Images

News | Mammography | March 03, 2021
March 3, 2021 — Attendance at regular ...
55-year-old woman who underwent screening mammogram and ultrasound 7 days after first COVID-19 vaccination dose. Screening mammogram and US demonstrated unilateral left axillary lymph node with cortical thickness of 5 mm on ultrasound (not shown). BI-RADS category 0 was assigned. Ultrasound from diagnostic work-up performed 7 days later showed no change in lymph node size. BI-RADS 3 was assigned. #COVIDvaccine #COVID19

55-year-old woman who underwent screening mammogram and ultrasound 7 days after first COVID-19 vaccination dose. Screening mammogram and US demonstrated unilateral left axillary lymph node with cortical thickness of 5 mm on ultrasound (not shown). BI-RADS category 0 was assigned. Ultrasound from diagnostic work-up performed 7 days later showed no change in lymph node size. BI-RADS 3 was assigned.

News | Breast Imaging | February 24, 2021
F-18 FES PET images of patients with ER+/PR+/HER2- invasive ductal carcinoma. Left panel: Progressive disease seen at the 8-week time-point in a patient on sequential therapy. Right panel: Stable disease through all 3 time-points, remaining on study therapy for 6.7 months until disease progression on combined vorinostat aromatase inhibitor therapy. Image created by Lanell M Peterson, Research Scientist, University of Washington Medical Oncology, Seattle WA.

F-18 FES PET images of patients with ER+/PR+/HER2- invasive ductal carcinoma. Left panel: Progressive disease seen at the 8-week time-point in a patient on sequential therapy. Right panel: Stable disease through all 3 time-points, remaining on study therapy for 6.7 months until disease progression on combined vorinostat aromatase inhibitor therapy. Image created by Lanell M Peterson, Research Scientist, University of Washington Medical Oncology, Seattle WA.

News | Molecular Imaging | February 22, 2021
February 22, 2021 — Molecular imaging
Examples of the imaging performance of XPCI-CT (b,e) compared to conventional specimen radiography (a,d) and benchmarked against histopathology (c,f). he top row focuses on the similarity between the XPCI-CT slice in (b) and the histological slice in (c). Arrow 1 indicates margin involvement, arrow 2 a variation in density in the internal structure of the tumour mass, arrow 3 tumour-induced inflammation. All this is confirmed by the histological slice in (c), and hardly visible in the conventional image in

Examples of the imaging performance of XPCI-CT (b,e) compared to conventional specimen radiography (a,d) and benchmarked against histopathology (c,f). he top row focuses on the similarity between the XPCI-CT slice in (b) and the histological slice in (c). Arrow 1 indicates margin involvement, arrow 2 a variation in density in the internal structure of the tumour mass, arrow 3 tumour-induced inflammation. All this is confirmed by the histological slice in (c), and hardly visible in the conventional image in (a). The bottom row focuses on the detection of small calcifications, a key feature in DCIS. These are undetectable in (d), detected in (e), enhanced in the maximum intensity projection (MIP) image at the bottom of (f), and confirmed by histopathology in the top part of (f). The scale bar [shown in (b) and (e)] is the same for all images apart from (f), which has its own scale. Red arrows in (e) and (f) indicate the microcalcifications. Image courtesy of Professor Alessandro Olivo

News | Breast Imaging | February 22, 2021
February 22, 2021 — A new X-ray imaging scanne
Screening strategy based on baseline breast density at age 40 may be effective and cost-effective for reducing breast cancer mortality

Getty Images

News | Breast Density | February 10, 2021
February 10, 2021 — A mammography screenin...
Comparison of breast cancer mortality rates (red squares) and distant-stage breast cancer incidence rates from SEER9 (blue dots) and SEER18 (green dots) per 100,000 for white women aged, A, 20–39, B, 40–69, and, C, 70–79 years (3,7,8).

Comparison of breast cancer mortality rates (red squares) and distant-stage breast cancer incidence rates from SEER9 (blue dots) and SEER18 (green dots) per 100,000 for white women aged, A, 20–39, B, 40–69, and, C, 70–79 years (3,7,8). Image courtesy of Radiology 

News | Breast Imaging | February 10, 2021
February 10, 2021 — Breast cancer death rates have stopped declining for women in the U.S.
After acquiring the molecular breast imaging (MBI) assets from GE Healthcare and Dilon Technologies, Inc., SmartBreast Corporation (SmartBreast), a privately held company focused on breast cancer screening and diagnosis, announced today that it has formed a partnership with FoxSemicon Integrated Technologies, Inc. (FITI) to manufacture molecular breast imaging (MBI) systems.
News | Breast Imaging | February 09, 2021
February 9, 2021 — After acquiring the...

Chart courtesy of the American Cancer Society

News | Breast Imaging | February 08, 2021
February 8, 2021 — Cancer ranks as a leading cause of death in every country in the world, and, for the first time,